» Articles » PMID: 39062458

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Jul 27
PMID 39062458
Authors
Affiliations
Soon will be listed here.
Abstract

The anterior gradient protein 2 (AGR2) plays a crucial role in facilitating the formation of protein disulfide bonds within the endoplasmic reticulum (ER). Research suggests that AGR2 can function as an oncogene, with its heightened expression linked to the advancement of hepatobiliary and pancreatic cancers through invasion and metastasis. Notably, AGR2 not only serves as a pro-oncogenic agent but also as a downstream targeting protein, indirectly fostering cancer progression. This comprehensive review delves into the established functions and expression patterns of AGR2, emphasizing its pivotal role in cancer progression, particularly in hepatobiliary and pancreatic malignancies. Furthermore, AGR2 emerges as a potential cancer prognostic marker and a promising target for immunotherapy, offering novel avenues for the treatment of hepatobiliary and pancreatic cancers and enhancing patient outcomes.

References
1.
Maresh E, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind E . Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010; 10:680. PMC: 3009682. DOI: 10.1186/1471-2407-10-680. View

2.
Zaytouni T, Tsai P, Hitchcock D, DuBois C, Freinkman E, Lin L . Critical role for arginase 2 in obesity-associated pancreatic cancer. Nat Commun. 2017; 8(1):242. PMC: 5556090. DOI: 10.1038/s41467-017-00331-y. View

3.
Hong X, Li Z, Hou J, Zhang H, Zhang C, Zhang J . Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells. BMC Cancer. 2021; 21(1):33. PMC: 7791724. DOI: 10.1186/s12885-020-07743-y. View

4.
Ma S, Wang W, Huang C, Zhang W, Sun Z . Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition. Oncotarget. 2015; 6(11):8807-21. PMC: 4496185. DOI: 10.18632/oncotarget.3556. View

5.
Negi H, Merugu S, Mangukiya H, Li Z, Zhou B, Sehar Q . Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study. Cancer Lett. 2019; 449:125-134. DOI: 10.1016/j.canlet.2019.01.025. View